# US 2004/0081965 A1 · DNA polymerases with reduced base analog detection activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081965 A1
- Document ID: US20040081965A1
- Status: Published application
- Kind: A1
- Application number: 10/280,962
- Filed: 2002-10-25
- Published: 2004-04-29
- Earliest claimed: 2002-10-25
- Assignees: Stratagene
- Inventors: Joseph A. Sorge; Holly H. Hogrefe; Madhushree Ghosh
- Web page: https://patentgrep.com/patent/US20040081965A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12Q 1/6869: Methods for sequencing
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to the generation and characterization of archaeal DNA polymerase mutants with reduced base analog detection activity. The invention further provides for archaeal dna polymerase mutants with reduced base analog detection activity containing additional mutations that modulate other DNA polymerase activities including DNA polymerization or 3′-5′ exonuclease activity. The invention also discloses methods and applications of DNA polymerases with reduced base analog detection activity.

## Claims

### Claim 1

A mutant archaeal DNA polymerase with a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution.

### Claim 2

A mutant Pfu DNA polymerase with a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93.

### Claim 3 (depends on 1, 2)

The mutant DNA polymerases of claim 1 or 2, wherein said mutant DNA polymerase further comprises a Glycine to Proline substitution at amino acid position 387 (G387P) that confers a reduced DNA polymerization phenotype to said mutant Pfu DNA polymerases.

### Claim 4 (depends on 1, 2)

The mutant DNA polymerases of claim 1 or 2, wherein said mutant DNA polymerase further comprises an Aspartate to Glutamic acid substitution at amino acid 141 (D141E) and a Glutamic acid to Alanine substitution at amino acid position 143 (D141E/E143A) that renders said mutant DNA polymerase 3′-5′ exonuclease deficient.

### Claim 5

An isolated polynucleotide comprising a nucleotide sequence encoding a mutant archacal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution.

### Claim 6

An isolated polynucleotide comprising a nucleotide sequence encoding a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93.

### Claim 7 (depends on 5, 6)

The isolated polynucleotide of claim 5 or 6, wherein said nucleotide sequence further comprises a Glycine to Proline substitution at amino acid position 387 (G387P) that confers a reduced DNA polymerization phenotype to said mutant Pfu DNA polymerases.

### Claim 8 (depends on 5, 6)

The isolated polynucleotide of claim 5 or 6, further comprising a nucleotide sequence encoding an Aspartate to Glutamic acid substitution at amino acid 141 (D141E) and a Glutamic acid to Alanine substitution at amino acid position 143 (E143A) that confers a 3′-5′ exonuclease deficient phenotype to said mutant Pfu DNA polymerases.

### Claim 9

A composition comprising a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution.

### Claim 10

A composition comprising a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93.

### Claim 11 (depends on 9, 10)

The composition of claim 9 or 10, further comprising Taq DNA polymerase.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said Taq DNA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.

### Claim 13 (depends on 9, 10, 12)

The composition of claim 9, 10 or 12, further comprising a PCR enhancing factor and/or an additive.

### Claim 14 (depends on 9, 10)

The composition of claim 9 or 10, further comprising a Pfu G387P/V93R or G387P/V93E double mutant DNA polymerase.

### Claim 15 (depends on 14)

The composition of claim 14, further comprising a PCR enhancing factor and/or an additive.

### Claim 16 (depends on 10)

The composition of claim 10, further comprising a Pfu V93R/D141E/E143A triple mutant DNA polymerase or a V93E/D141E/E143A triple mutant.

### Claim 17 (depends on 16)

The composition of claim 16, further comprising a PCR enhancing factor and/or an additive.

### Claim 18 (depends on 9, 10)

The composition of claims 9 or 10, further comprising a Thermus DNA ligase or a FEN-1 nuclease.

### Claim 19 (depends on 18)

The composition of claim 18, further comprising a PCR enhancing factor and/or an additive.

### Claim 20

A kit comprising a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution, and packaging materials therefor.

### Claim 21

A kit comprising a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93.

### Claim 22 (depends on 20, 21)

The kit of claim 20 or 21, further comprising a PCR enhancing factor and/or an additive.

### Claim 23 (depends on 20, 21)

The kit of claim 20 or 21, further comprising Taq DNA polymerase.

### Claim 24 (depends on 23)

The kit of claim 23, wherein said Taq DNA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.

### Claim 25 (depends on 23)

The kit of claim 23, further comprising a PCR enhancing factor and/or an additive.

### Claim 26 (depends on 20, 21)

The kit of claim 20 or 21, further comprising a Pfu G387P/V93R double mutant DNA polymerase.

### Claim 27 (depends on 26)

The kit of claim 26, further comprising a PCR enhancing factor and/or an additive.

### Claim 28 (depends on 21)

The kit of claim 21, wherein said mutant Pfu DNA polymerase further comprises a D141E/E143A mutation.

### Claim 29 (depends on 28)

The kit of claim 28, further comprising a PCR enhancing factor and/or an additive.

### Claim 30 (depends on 20, 21)

The kit of claims 20 or 21, further comprising Thermus DNA ligase, FEN-1 nuclease or a PCR enhancing factor and/or an additive and packaging materials therefor.

### Claim 31

A method for DNA synthesis comprising:
(a) providing a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DNA synthesis.

### Claim 32

A method for DNA synthesis comprising:
(a) providing a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93; and
(b) contacting said enzyme with a nucleic acid template, wherein said enzyme permits DNA synthesis.

### Claim 33

A method for cloning of a DNA synthesis product comprising:
(a) providing a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archaeal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution; and
(b) contacting said mutant archaeal DNA polymerase with a nucleic acid template, wherein said mutant archaeal DNA polymerase permits DNA synthesis to generate a synthesized DNA product; and
(c) inserting said synthesized DNA product into a cloning vector.

### Claim 34

A method for cloning of a DNA synthesis product comprising:
(a) providing a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93;
(b) contacting said mutant Pfu DNA polymerase with a nucleic acid template, wherein said mutant Pfu DNA polymerase permits DNA synthesis to generate a synthesized DNA product; and
(c) inserting said synthesized DNA product into a cloning vector.

### Claim 35 (depends on 31, 32, 33)

The method of claims 31, 32, 33, or 34, further comprising a Thermus DNA ligase or a FEN-1 nuclease.

### Claim 36

A method for sequencing DNA comprising the step of:
(a) providing a mutant archaeal DNA polymerase having a reduced base analog detection activity, wherein said mutant archacal DNA polymerase comprises a mutation at position V93, wherein said mutation is a Valine to Arginine substitution or a Valine to Glutamic acid substitution;
(b) generating chain terminated fragments from the DNA template to be sequenced with said mutant archaeal DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DNA from the sizes of said fragments.

### Claim 37

A method for sequencing DNA comprising the step of:
(a) providing a mutant Pfu DNA polymerase having a reduced base analog detection activity, wherein said mutant Pfu DNA polymerase comprises a Valine to Arginine substitution or a Valine to Glutamic acid substitution at amino acid position V93;
(b) generating chain terminated fragments from the DNA template to be sequenced with said mutant Pfu DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and
(c) determining the sequence of said DNA from the sizes of said fragments.

### Claim 38 (depends on 31, 32, 33, 34, 36, 37)

The method of claim 31, 32, 33, 34, 36 or 37, further providing Taq DNA polymerase.

### Claim 39 (depends on 38)

The method of claim 38, wherein said Taq DNA polymerase is at a 2 fold, 5 fold, 10 fold or 100 fold lower concentration than said mutant Pfu DNA polymerase.

### Claim 40 (depends on 31, 32, 33, 34, 36, 37)

The method of claim 31, 32, 33, 34, 36 or 37, further comprising a PCR enhancing factor and/or an additive.

### Claim 41 (depends on 31, 32, 33, 34)

The method of claim 31, 32, 33 or 34 further providing a Pfu G387P/V93R double mutant DNA polymerase.

### Claim 42 (depends on 41)

The method of claim 41, further comprising a PCR enhancing factor and/or an additive.

### Claim 43 (depends on 31, 32, 33, 34, 36, 37)

The method of claim 31, 32, 33, 34, 36 or 37, further providing a Pfu D141E/E143A double mutant DNA polymerase.

### Claim 44 (depends on 43)

The method of claim 43, further comprising a PCR enhancing factor and/or an additive.
